Squarepoint’s Editas Medicine EDIT Stock Holding History

Squarepoint’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,700	Closed	-$30.1K	–	4781
2024 Q4	$30.1K	Buy	+23,700	New	+$60.4K	﹤0.01%	4905

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Squarepoint's EDIT Position: Q1 2026 in Review

Squarepoint sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 91,846 shares — an estimated $188K sold.

Squarepoint first reported a position in EDIT in Q2 2016 and held it in 27 quarters. The position peaked at $6.67M in Q1 2024. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Squarepoint reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 91,846 Editas Medicine shares in Q1 2026, an estimated $188K.
Squarepoint first reported a position in Editas Medicine in Q2 2016 and held it in 27 quarters.
Squarepoint's Editas Medicine position peaked at $6.67M in Q1 2024.
208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.